In today’s clinical oncology practice, the saying “no two cancers are alike” is more relevant than ever. I recently treated two patients with very similar advanced non-small cell lung cancer (NSCLC) who were both critically ill. However, molecular profiling revealed distinct genetic drivers for each case, leading to very different, highly customized treatment plans.
Patient presentation and initial assessment
Both patients, in their late 60s and never-smokers, presented with weight loss, worsening dyspnea, and a persistent cough. Imaging revealed bilateral lung masses with mediastinal lymphadenopathy and distant metastases, including bone lesions, consistent with stage IV lung adenocarcinoma. They were symptomatic but still ambulatory, with an ECOG performance status of 2.
Biopsies confirmed adenocarcinoma NSCLC. In accordance with current guidelines and institutional protocols, we performed comprehensive molecular profiling using a next-generation sequencing panel to identify actionable mutations up front. This step proved to be the turning point in both of their treatment journeys.
Molecular profiling: Understanding tumor biology
Patient 1’s tumor contained an EGFR exon 19 deletion, which is one of the most common driver mutations in non-small cell lung cancer (NSCLC). This mutation leads to continuous activation of the EGFR tyrosine kinase domain, resulting in uncontrolled tumor growth.
In contrast, Patient 2’s tumor exhibited an EML4-ALK fusion gene rearrangement. This is a potent oncogenic driver that characterizes a distinct molecular subset of NSCLC and shows high sensitivity to ALK inhibitors. Although both patients had similar staging and clinical presentations, the underlying oncogenic pathways were fundamentally different, requiring distinct molecularly targeted treatments.
Treatment strategy and rationale
Patient 1: Targeted EGFR inhibition
For Patient 1, we initiated treatment with osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI) that irreversibly binds to mutant EGFR and blocks downstream signaling through tumor-promoting pathways, including PI3K-AKT and RAS-RAF-MEK. Current guidelines recommend osimertinib as the first-line treatment for common sensitizing EGFR mutations, such as exon 19 deletions and L858R. This is due to its ability to provide superior progression-free survival rates and a more favorable toxicity profile compared to earlier TKIs or chemotherapy. Clinically, this led to improved breathing, reduced coughing, and a gradual enhancement in performance status over the following weeks.
Patient 2: ALK inhibitor therapy
For Patient 2, we began treatment with alectinib, a potent and selective ALK inhibitor that has shown significantly longer progression-free survival, durable overall survival, and better central nervous system disease control compared to crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). Additionally, it offers a more favorable tolerability profile. Practically, this translates to a greater likelihood of the cancer being controlled for a longer period, including in the brain, with fewer severe side effects than those associated with a first-generation ALK inhibitor. Within a few weeks, he experienced marked improvements in shortness of breath, energy levels, and chest discomfort, highlighting the effectiveness of directly targeting ALK-driven oncogenesis.
Why we initially avoided chemotherapy and immunotherapy
For both patients, we intentionally avoided upfront platinum-based chemotherapy and immune checkpoint inhibitors. In cases involving sensitizing EGFR mutations or ALK fusions, targeted tyrosine kinase inhibitors (TKIs) offer higher response rates and longer progression-free survival compared to chemotherapy, with reduced systemic toxicity. Additionally, immune checkpoint inhibitors have demonstrated limited benefits, and in some instances, increased toxicity, in EGFR-mutated non-small cell lung cancer (NSCLC), especially when used before or instead of targeted therapy. Therefore, precision oncology involves not only selecting appropriate treatments but also carefully deciding what to withhold.
Monitoring and managing resistance
We monitored the clinical status of both patients closely and conducted regular imaging follow-ups. The inevitable development of acquired resistance to targeted therapy remains one of the major challenges in managing driver-mutated NSCLC. For osimertinib, common resistance mechanisms include secondary EGFR mutations and MET amplification, often necessitating repeat tissue or liquid biopsies, as well as consideration of clinical trials exploring novel combinations.
In the case of ALK-positive disease, several next-generation ALK TKIs, such as brigatinib, ceritinib, alectinib, lorlatinib, and ensartinib, are now available and can be sequenced after initial ALK inhibitor failure. This sequencing is guided by the specific resistance mechanisms, prior TKI exposure, and patient-specific factors. This evolving sequence of ALK inhibitors often enables clinicians to restore disease control, even in patients with brain metastases, when the first-line drug ceases to be effective.
Multidisciplinary care and patient support
These cases highlighted the importance of having a multidisciplinary team that included oncologists, pathologists, molecular biologists, radiologists, nursing staff, and supportive care specialists. Rapid turnaround for sequencing, precise interpretation of molecular reports, and coordinated implementation of targeted therapies were critical for timely treatment initiation. Equally vital were patient education, proactive monitoring of toxicity, and symptom-directed supportive care, all aimed at maintaining quality of life throughout treatment.
Conclusion
These two patients with stage IV lung adenocarcinoma initially appeared almost indistinguishable, yet their tumors required very distinct, mechanism-specific treatments based on molecular profiling. Precision oncology not only improved their quality of life and extended meaningful time even in advanced disease, but it also fundamentally transformed our understanding of “similar” cancers. This experience has strengthened my commitment as a clinician to integrate comprehensive molecular profiling into routine lung cancer care and to advocate for personalized treatment strategies that genuinely respect the unique biology of each patient’s tumor.
Sunny Garg is an oncologist in India.
